Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial.
BMC pharmacology & toxicology（2023）
摘要
This study was registered on 18 June 2022 at the Chinese Clinical Trial Registry (ChiCTR2200061250).
更多查看译文
关键词
COVID-19, Critical ill COVID-19, Proxalutamide, Severe COVID-19
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要